FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Commodities

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileAltimmune, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
ALT
Altimmune, Inc. Stock AnalysisComprehensive stock analysis for Altimmune, Inc. (ALT) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisALT
ALT
Altimmune, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
ALT
  1. Home
  2. Stocks
  3. Altimmune, Inc.

Altimmune, Inc.

🇺🇸ALT•NASDAQ

Altimmune, Inc.

🇺🇸ALT•NASDAQ
Market cap
$303.56M
Sentiment

Your view on ALT

Mkt Cap
$303.56M
Sentiment
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Altimmune, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Vipin K. Garg
Headquarters
910 Clopper Road, Gaithersburg, MD, US
Industry
Biotechnology
Sector
Healthcare
CEO
Vipin K. Garg
Headquarters
910 Clopper Road, Gaithersburg, MD, US
Description

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases.

The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis.

It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus.

The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Financial Data

Stock Data

Price chart, volume, and trading data.

What moved it

FRC Fair Value Algorithm

What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.

About this section

Fair value for Altimmune, Inc. from FRC's valuation model, read against the market price. ALT last traded at $1.56; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Altimmune, Inc.. Starting points for Altimmune, Inc.: EPS -$0.51, beta 0.18 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Altimmune, Inc.. Altimmune, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Altimmune, Inc.. Trailing twelve-month EPS for Altimmune, Inc. stands at -$0.51. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Third partyAs of Nov 18, 2026 · USD

Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.

Current price

—

live quote

Analysts' target

$10.83

average of 3 firms, last 12 months

 

$10.83

Low $2.50

Median $10.00

High $20.00

 

Analyst Ratings

Buy4 firms, last 12 months
  • Strong Buy0
  • Buy4
  • Hold0
  • Sell0
  • Strong Sell0

Earnings Estimate

EPSCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate-$0.17-$0.16-$0.61-$0.67
Low estimate-$0.21-$0.17-$0.68-$0.90
High estimate-$0.15-$0.14-$0.56-$0.55
No. of analysts4367
Year-ago EPS-$0.27-$0.18-$1.00—
Growth+37.1%+9.1%+38.9%—

Revenue Estimate

RevenueCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$1750.00$18.49M$1875.00$25.73M
Low estimate$1750.00$18.49M$1875.00$25.73M
High estimate$1750.00$18.49M$1875.00$25.73M
No. of analysts9966
Year-ago revenue$26000.00$0.00$41000.00—
Growth-93.3%—-95.4%—
Recent analyst actions15 rating and price-target changes, latest Sep 23, 2026 — with the analyst, firm and source

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga; as of Nov 18, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Altimmune, Inc.. Altimmune, Inc. has reported as a listed company since 2017. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold ALT20 companies · 8 funds
Compare ALT with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis

Peer companies

Market cap

  • ABUSArbutus Biopharma CorporationBiotechnology$619M
  • ALGSAligos Therapeutics, Inc.Biotechnology$10M
  • ASMBAssembly Biosciences, Inc.Biotechnology$436M
  • BMEABiomea Fusion, Inc.Biotechnology$38M
  • ENTAEnanta Pharmaceuticals, Inc.Biotechnology$311M
  • GPCRStructure Therapeutics Inc.Biotechnology$1.1B
  • INDPIndaptus Therapeutics, Inc.Biotechnology$391M
  • IVAInventiva S.A.Biotechnology$173M

More Biotechnology companies

  • PSYBFPsyBio Therapeutics Corp.OTC$1,275
  • PTCHFPureTech Health plcOTC$410M
  • PTCTPTC Therapeutics, Inc.NASDAQ$5.1B
  • PTGXProtagonist Therapeutics, Inc.NASDAQ$8.1B
  • PTHSPelthos Therapeutics Inc.AMEX$28M
  • PTIXProtagenic Therapeutics, Inc.NASDAQ$470,654
  • PTNPalatin Technologies, Inc.NASDAQ$11M
  • PTX.AXPrescient Therapeutics LimitedASX
  • PULMPulmatrix, Inc.NASDAQ$5M
  • PVCTProvectus Biopharmaceuticals, Inc.OTC$19M
  • PVLAPalvella Therapeutics, Inc.NASDAQ$2.1B
  • PXMDPaxMedica, Inc. Common StockOTC$37,879

ETFs holding Altimmune, Inc.

% of the fund

  • IWMiShares Russell 2000 ETF$76.6B in assets0.01%
  • XBIState Street SPDR S&P Biotech ETF$10.0B in assets0.07%
  • VTIVanguard Total Stock Market ETF$689.2B in assets0.00%
  • VXFVanguard Extended Market ETF$30.2B in assets0.00%
  • BBCVirtus LifeSci Biotech Clinical Trials ETF$32M in assets0.49%
  • SBIOALPS Medical Breakthroughs ETF$187M in assets0.20%
  • IWCiShares Micro-Cap ETF$1.2B in assets0.08%
  • VTWVVanguard Russell 2000 Value ETF$1.3B in assets0.03%

Largest holders first, then the funds most concentrated in ALT.

Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Altimmune, Inc., and how their positions are changing. At a $303.6M market value, institutional positions materially move Altimmune, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Altimmune, Inc. executives and directors. Shares of Altimmune, Inc. have traded between $2.90 and $10.88 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Altimmune, Inc.. Coverage tracks Altimmune, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Altimmune, Inc.

ALT Analysis
Fair
Past1
Growth5
Health4
Profit1
Value1

News

Latest Market News